This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Here's Why You Should Retain Cardinal Health (CAH) Stock
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.
HealthEquity (HQY) Set to Acquire WageWorks for $2 Billion
by Zacks Equity Research
HealthEquity (HQY) is set to acquire WageWorks in an all-cash deal of about $2 billion. The buyout is expected to help HealthEquity to expedite the market-wide transition to HSAs.
Here's Why You Should Hold on to Surmodics (SRDX) Stock Now
by Zacks Equity Research
Surmodics (SRDX) is gaining from consistent growth In Vitro Diagnostics (IVD) unit and persistent efforts to boost R&D functionalities.
Here's Why You Should Hold on to McKesson (MCK) Stock Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market.
Here's Why You Should Retain Allscripts (MDRX) Stock Now
by Zacks Equity Research
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Here's Why You Should Invest in Cooper Companies Stock Now
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions.
Here's Why You Should Hold on to Stryker (SYK) Stock Now
by Zacks Equity Research
Stryker (SYK) is gaining steadily from strong international growth and robust product portfolio. However, unfavorable pricing environment remains a woe.
Wall Street Foresees a Fed Rate Cut: Winners & Losers
by Tirthankar Chakraborty
Some analysts have started to price in "insurance cuts," which means they are expecting the Fed to cut rates right before a downturn in order to save the economy.
AMN Healthcare (AMN) Closes Advanced Medical Acquisition
by Zacks Equity Research
AMN Healthcare (AMN) completes Advanced Medical buyout that will help the former to boost offerings in some of the fastest growing and very important care settings.
Here's Why You Should Hold on to PRA Health (PRAH) Stock Now
by Zacks Equity Research
PRA Health (PRAH) is gaining steadily from expansion in international markets, solid 2019 outlook and growing CRO industry. However, tough capital spending environment remains a woe.
Medical Products Industry Outlook: Growth Prospects Radiant
by Trina Mukherjee
Growth prospects look bright for the Zacks Medical Products industry, thanks to AI, Medical Mechatronics and Robotics and rampant M&As.
Here's Why You Should Add Cardiovascular Systems (CSII) Stock
by Zacks Equity Research
Cardiovascular Systems (CSII) gains on high investors' confidence, courtesy of consistent positive results.
Masimo's O3 Oximetry Gets FDA Nod, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) gets FDA nod for its O3 Regional Oximetry that will help in delivering accurate measurement with respect to neonatal patients.
Ecolab Unveils Innovative Tested Tool to Improve Food Safety
by Zacks Equity Research
Ecolab's (ECL) innovative tested tool aims to improve food safety and ensure customer safety.
Here's Why You Should Invest in Integer Holdings (ITGR) Stock
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
Here's Why You Should Retain HMS Holdings (HMSY) Stock
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from the growing PI and TPM analytical services. However, stiff competition remains a concern.
Here's Why You Should Retain NextGen Healthcare (NXGN) Stock
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Invest in DexCom (DXCM) Stock Now
by Zacks Equity Research
DexCom (DXCM) is gaining traction from lucrative glucose monitoring market, solid international market presence and strong product portfolio.
Here's Why You Should Hold on to Medidata (MDSO) Stock Now
by Zacks Equity Research
Medidata Solutions (MDSO) continues to benefit from solid R&D focus, Rave Genomics platform and cloud-based services. However, stiff competition remains a concern.
Cardiovascular Systems (CSII) Up 6.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Cardiovascular Systems (CSII) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Bet on Merit Medical (MMSI) Stock Now
by Zacks Equity Research
Merit Medical (MMSI) continues to benefit from solid product pipeline, HeRO product line and persistent focus on R&D.
Here's Why You Should Consider Betting On CONMED Stock Now
by Zacks Equity Research
CONMED (CNMD) continues to benefit from robust international sales, broad product portfolio and continued focus on R&D.
ABIOMED Gets FDA Confirmation of the Safety of Impella RP
by Zacks Equity Research
ABIOMED (ABMD) receives the FDA confirmation of the safety and effectiveness of the company's Impella RP heart pump.
Masimo Gets FDA Nod for Radius PPG, Boosts Patient Monitoring
by Zacks Equity Research
Masimo (MASI) receives FDA 510 (k) clearance for Radius PPG, which is set to become an important breakthrough in patient monitoring.
Here's Why You Should Retain Cooper Companies (COO) Stock
by Zacks Equity Research
Cooper Companies (COO) is gaining traction from expansion in international markets, robust product portfolio across segments and prudent acquisitions. However, forex volatility remains a concern.